A prospective surveillance study of inhibitor development in haemophilia A patients following a population switch to a third-generation B-domain-deleted recombinant factor VIII.

E DubéA BonnefoyC MerlenJ-F CastillouxS CloutierC DemersC A SabapathyJ St-LouisC VezinaM WarnerGeorges-Etienne Rivard

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2018)

Our surveillance study shows comparable inhibitor development to similar published studies. A significant increase in FVIII utilization was noted for the whole cohort, switchers and non-switchers. Lastly, no clinically significant changes were observed in ABR for joint bleeds, but a difference for non-joint bleed ABRs was observed in switchers.

Keyphrases

public health
end stage renal disease
newly diagnosed
randomized controlled trial
systematic review
cell free
meta analyses